Lactoferrin as an agent in the prevention of organ...

Details Lactoferrin as an agent in the prevention of organ... Lactoferrin as an agent in the prevention of organ...

2009-08-17

2011-11-15

Kim, Yunsoo (Department: 1644)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S006900, C514S023000

Reexamination Certificate

active

08058234

ABSTRACT:
The present invention relates to methods of using lactoferrin (LF) to treat, prevent or reduce the incidence of organ transplant rejection and graft-versus-host-disease. More particularly, the present invention relates to methods of reducing an immune response against miss-matched transplanted organs such as kidney, heart, lung, liver, pancreas and stem cells by administering a composition of lactoferrin to the recipient patients. In addition, this invention relates to the treatment of bone marrow transplant (BMT) donors with lactoferrin to attenuate the development of graft-versus-host-disease in the recipients. Moreover, this invention relates to the treatment of xenograft organ donors with lactoferrin to attenuate the development of graft rejection in the recipients.

REFERENCES:
patent: 4977137 (1990-12-01), Nichols et al.
patent: 5006333 (1991-04-01), Saifer et al.
patent: 5198419 (1993-03-01), Ando et al.
patent: 5571691 (1996-11-01), Conneely et al.
patent: 5571697 (1996-11-01), Conneely et al.
patent: 5571896 (1996-11-01), Conneely et al.
patent: 5674495 (1997-10-01), Bowersock et al.
patent: 5712247 (1998-01-01), Wu et al.
patent: 5766939 (1998-06-01), Conneely et al.
patent: 5849881 (1998-12-01), Conneely et al.
patent: 5919913 (1999-07-01), Nuyens et al.
patent: 5955316 (1999-09-01), Conneely et al.
patent: 6066469 (2000-05-01), Kruzel et al.
patent: 6080559 (2000-06-01), Conneely et al.
patent: 6100054 (2000-08-01), Conneely et al.
patent: 6111081 (2000-08-01), Conneely et al.
patent: 6228614 (2001-05-01), Conneely et al.
patent: 6277817 (2001-08-01), Kruzel et al.
patent: 6333311 (2001-12-01), Nuijens et al.
patent: 6399570 (2002-06-01), Mann
patent: 6455687 (2002-09-01), Kruzel et al.
patent: 6635447 (2003-10-01), Conneely et al.
patent: 7592306 (2009-09-01), Varadhachary et al.
patent: 2002/0072596 (2002-06-01), Ruben et al.
patent: 2003/0105006 (2003-06-01), Mann
patent: 2003/0190303 (2003-10-01), Kimber et al.
patent: 2004/0009895 (2004-01-01), Varadhachary et al.
patent: 2004/0009896 (2004-01-01), Glynn et al.
patent: 2004/0023334 (2004-02-01), Prior
patent: 2004/0082504 (2004-04-01), Varadhachary et al.
patent: 2004/0142037 (2004-07-01), Engelmayer et al.
patent: 2004/0151784 (2004-08-01), Varadhachary et al.
patent: 2004/0152623 (2004-08-01), Varadhachary et al.
patent: 2004/0152624 (2004-08-01), Varadhachary et al.
patent: 2004/0176276 (2004-09-01), Varadhachary et al.
patent: 2005/0004006 (2005-01-01), Engelmayer et al.
patent: 2005/0019342 (2005-01-01), Varadhachary et al.
patent: 2005/0064546 (2005-03-01), Conneely et al.
patent: 2005/0075277 (2005-04-01), Varadhachary et al.
patent: 0 426 924 (1991-05-01), None
patent: 7-316069 (1995-12-01), None
patent: WO 2001/72322 (2001-10-01), None
patent: WO 2002/03910 (2002-01-01), None
Chan et al., “Autoantibody formation after allogeneic bone marrow transplantation: correlation with the reconstitution of CD5+B cells and occurrence of graft-versus-host disease,”Pathology, 29(2):184-188, 1997.
Cunha, “Intravenous-to-oral antibiotic switch therapy,”Postgraduate Medicine Online, 101(4), 1997.
Inoue et al., “Lactoferrin for gut GVHD,”Bone Marrow Transplantation, 28(11):1091-1092, 2001.
International Preliminary Examination Report issued in International Application No. PCT/US2003/39265, completed Apr. 6, 2006.
International Search Report issued in International Application No. PCT/US2003/39265, mailed Apr. 18, 2005.
Kuby et al., “Transplantation Immunology,”Immunology, 4thEd. Freeman and Co., Chapter 21, pp. 517-537, 2000.
Kunzendorf et al., “The Th1-Th2 paradigm in 1998: law of nature or rule with exceptions,”Nephrology Dialysis Transplantation3, 13:2445-2448, 1998.
Mencucci et al., “Ophthalmological aspects in allogenic bone marrow transplantation: Sjögren-like syndrome in graft-versus-host disease,”European Journal of Ophthalmology, 7(1):13-18, 1997.
Nikolic et al., “Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets,”The Journal of Clinical Investigation, 105(9):1289-1298, 2000.
Perico et al., “Delayed graft function in kidney transplantation,”Lancet, 364:1814-1827, 2004.
Skolnick and Fetrow, “From genes to protein structure and function: novel applications of computational approaches in the genomic era,”Trends in Biotech., 18:34-39, 2000.
Suthanthiran, “Human renal allograft rejection: molecular characterization,”Nephrol Dial Transplant, 13[Suppl. 1]:21-24, 1998.

Affiliated with

Also associated with

Rating

Lactoferrin as an agent in the prevention of organ... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Lactoferrin as an agent in the prevention of organ..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lactoferrin as an agent in the prevention of organ... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4264005